🌐Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
🔴 Serious hazard — Reported risk: Το προϊόν περιέχει αλλεργιογόνα αρώματα (Linalool, Citronellol, Alpha-isomethyl ionone, Hexyl cinnamal, Limonene και Coumarin), τα οποία δεν αναφέρονται στον κατάλογο συστατικών. Η παράλειψη αναφοράς της παρουσίας αλλεργιογόνου αρώματος στην επισήμανση σε προϊόντα που παραμένουν στο δέρμα μπορεί να προκαλέσει δερματίτιδα/έκζεμα ή πιο σοβαρές δερματικές αντιδράσεις σε άτομα που έχουν ήδη ευαισθητοποιηθεί. Το προϊόν δεν συμμορφώνεται με τον κανονισμό για τα καλλυντικά προϊόντα.
Action taken by the authority
Type of economic operator to whom the measure were ordered
Distributor
Category of measure
Removal of this product listing by the online marketplace
Date of entry into force
16/10/2025
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.
Product Name (original English): BIOPRO ALOE 24
Risk Description (original English): The product contains allergenic fragrances (Linalool, Citronellol, Alpha-isomethyl ionone, Hexyl cinnamal, Limonene and Coumarin), which are not mentioned in the list of ingredients. Failure to mention the presence of an allergenic fragrance in the labelling in leave-on products may cause dermatitis/eczema, or more serious skin reactions in already sensitized persons.
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.